Cell Therapeutics, Inc. (CTI) Announces ASCO Activities
Cell Therapeutics, Inc. (CTI) today announced presentations of interest on lung cancer and on its development candidate XYOTAX(TM) (paclitaxel poliglumex) at the 43rd American Society of Clinical Oncology (ASCO) Annual Meeting, being held June 1-5, 2007, in Chicago.
This entry was posted on Tuesday, May 29th, 2007 at 10:02 am and is filed under Research. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.